| Literature DB >> 35108378 |
Lisa T Jansen1, Nianlan Yang2, Julia M W Wong1, Tapan Mehta2, David B Allison3, David S Ludwig1, Cara B Ebbeling1.
Abstract
OBJECTIVE: Consuming ≥150 g/day carbohydrate is recommended for 3 days before an oral glucose tolerance test (OGTT) for diabetes diagnosis. For evaluation of this recommendation, time courses of glycemic changes following transition from a very-low-carbohydrate (VLC) to high-carbohydrate diet were assessed with continuous glucose monitoring (CGM). RESEARCH DESIGN AND METHODS: After achieving a weight loss target of 15% (±3%) on the run-in VLC diet, participants (18-50 years old, BMI ≥27 kg/m2) were randomly assigned for 10 weeks to one of three isoenergetic diets: VLC (5% carbohydrate and 77% fat); high carbohydrate, high starch (HC-Starch) (57% carbohydrate and 25% fat, including 20% refined grains); and high carbohydrate, high sugar (HC-Sugar) (57% carbohydrate and 25% fat, including 20% sugar). CGM was done throughout the trial (n = 64) and OGTT at start and end (n = 41). All food was prepared in a metabolic kitchen and consumed under observation.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35108378 PMCID: PMC8918196 DOI: 10.2337/dc21-1970
Source DB: PubMed Journal: Diabetes Care ISSN: 0149-5992 Impact factor: 19.112
Figure 1Study design.
Characteristics of study participants
| Completers | CGM analyses | OGTT analysis | |
|---|---|---|---|
| Participants, | 70 | 64 | 41 |
| Sex | |||
| Female | 29 (41.4) | 24 (37.5) | 27 (65.9) |
| Male | 41 (58.6) | 40 (62.5) | 14 (34.2) |
| Race | |||
| White | 55 (78.6) | 51 (79.7) | 30 (73.2) |
| Black | 7 (10.0) | 6 (9.4) | 6 (14.6) |
| Other or no response | 8 (11.4) | 7 (10.9) | 5 (12.2) |
| Ethnicity | |||
| Non-Hispanic | 51 (72.9) | 47 (73.4) | 27 (65.9) |
| Hispanic | 19 (27.1) | 17 (26.6) | 14 (34.1) |
| Cohort | |||
| 1 | 6 (8.6) | 0 (0) | 6 (14.6) |
| 2 | 13 (18.6) | 13 (20.3) | 13 (31.7) |
| 3 | 22 (31.4) | 22 (34.4) | 22 (53.7) |
| 4 | 29 (41.4) | 29 (45.3) | 0 (0.0) |
| Measurements at PRE, mean (SD) | |||
| Age, years | 34.0 (9.2) | 34.2 (9.1) | 35.6 (9.2) |
| Height, cm | 172.6 (9.3) | 173.5 (9.1) | 169.9 (8.7) |
| Weight, kg | 101.2 (16.7) | 102.2 (16.8) | 95.5 (13.6) |
| BMI, kg/m2 | 34.0 (5.1) | 34.0 (5.2) | 33.1 (4.2) |
| Fasting glucose, mg/dL | 101.1 (8.0) | 101.3 (7.5) | 100.1 (7.7) |
| Fasting glucose, mmol/L | 5.6 (0.4) | 5.6 (0.4) | 5.6 (0.4) |
| 2-h glucose, mg/dL | 139.5 (38.8) | 137.9 (39.2) | 145.0 (42.4) |
| 2-h glucose, mmol/L | 7.7 (2.2) | 7.7 (2.2) | 8.0 (2.4) |
| Fasting insulin, μIU/mL | 16.0 (10.1) | 15.7 (10.0) | 15.1 (9.4) |
| Fasting insulin, pmol/L | 95.8 (60.8) | 94.4 (60.2) | 90.9 (56.5) |
| Measurements at START, mean (SD) | |||
| Weight, kg | 85.8 (14.1) | 86.6 (14.2) | 81.4 (12.0) |
| BMI, kg/m2 | 28.8 (4.4) | 28.8 (4.5) | 28.2 (3.8) |
| Fasting glucose, mg/dL | 81.5 (7.7) | 81.5 (7.9) | 81.0 (6.3) |
| Fasting glucose, mmol/L | 4.5 (0.4) | 4.5 (0.4) | 4.5 (0.4) |
| 2-h glucose, mg/dL | 148.4 (40.5) | 146.1 (41.3) | 156.0 (42.5) |
| 2-h glucose, mmol/L | 8.2 (2.2) | 8.1 (2.3) | 8.7 (2.4) |
| Fasting insulin, μIU/mL | 5.9 (3.7) | 5.7 (3.7) | 5.6 (3.3) |
| Fasting Insulin, pmol/L | 35.5 (22.2) | 34.5 (22.1) | 33.7 (19.6) |
Data are n (%) unless otherwise indicated.
Of the 77 randomized participants, 70 were retained at END (completers).
CGM data were available for 64 retained participants (because a different device, yielding incomparable data, was used for 6 participants in the initial cohort).
OGTT data were available for 41 retained participants (due to elimination of the OGTT at END for 29 participants in the final cohort as part of risk mitigation in response to COVID-19).
OGTT curves for glucose and insulin at PRE and START are presented in Supplementary Fig. 2.
Linear trends in glucose dynamics measured by CGM from week 2 to week 9 of the test diet period*
| Outcome | VLC ( | HC-Starch ( | HC-Sugar ( | |||
|---|---|---|---|---|---|---|
| Estimate (95% CI) |
| Estimate (95% CI) |
| Estimate (95% CI) |
| |
| Fasting glucose | ||||||
| mg/dL, per week | −0.0 (−0.5, 0.5) | 0.981 | −0.7 (−1.2, −0.2) | 0.004 | −0.6 (−1.1, −0.1) | 0.029 |
| mmol/L, per week | −0.00 (−0.03, 0.03) | −0.04 (−0.07, −0.01) | −0.03 (−0.06, −0.00) | |||
| Peak glucose | ||||||
| mg/dL, per week | −0.4 (−1.1, 0.3) | 0.223 | −1.6 (−2.3, −0.9) | 0.000 | −1.2 (−1.9, −0.5) | 0.002 |
| mmol/L, per week | −0.02 (−0.06, 0.01) | −0.09 (−0.12, −0.05) | −0.07 (−0.11, −0.03) | |||
| 2-h glucose | ||||||
| mg/dL, per week | −0.2 (−0.8, 0.4) | 0.537 | −1.2 (−1.9, −0.6) | 0.000 | −0.5 (−1.2, 0.2) | 0.191 |
| mmol/L, per week | −0.01 (−0.05, 0.02) | −0.07 (−0.10, −0.03) | −0.03 (−0.06, 0.01) | |||
Data are mean estimate (95% CI). Null hypothesis, slope = 0.
Within–diet group estimates of slopes derived from linear regression model of weekly means from week 2 to week 9 of the test diet period.
Figure 2Segmented regression modeling of CGM slope dynamics from week 2 to week 9 of the test diet period. Data are depicted as estimate means from the models for fasting (A) and 2-h (B) glucose. Estimated change points are indicated by arrows. Data points for week 0 (last week of run-in diet) and week 1 (first week of test diet) are raw means to illustrate the full time course of changes.
Frequency of abnormal diabetes screening tests at START and END by diet group*
| Diagnosis | VLC ( | HC-Starch ( | HC-Sugar ( | |||
|---|---|---|---|---|---|---|
| START | END | START | END | START | END | |
| Abnormal HbA1c | ||||||
| ≥5.7% | 0 | 0 | 0 | 0 | 0 | 0 |
| ≥39 mmol/mol | ||||||
| Abnormal fasting glucose | ||||||
| ≥100 mg/dL | 0 | 0 | 0 | 1 | 0 | 4 |
| ≥5.6 mmol/L | ||||||
| Abnormal glucose tolerance (2-h glucose) | ||||||
| ≥140 mg/dL | 10 | 10 | 9 | 7 | 8 | 2 |
| ≥7.8 mmol/L | ||||||
Frequency of participants presenting with abnormal diabetes screening tests at START (when all were habituated to a VLC prior to randomization) and END (during week 10 of test diet period).